과제정보
A.R.K. acknowledges support from NIH grant R37GM042699.
참고문헌
- Aartsma-Rus, A. and Corey, D.R. (2020). The 10th oligonucleotide therapy approved: golodirsen for Duchenne muscular dystrophy. Nucleic Acid Ther. 30, 67-70. https://doi.org/10.1089/nat.2020.0845
- Bennett, C.F. (2019). Therapeutic antisense oligonucleotides are coming of age. Annu. Rev. Med. 70, 307-321. https://doi.org/10.1146/annurev-med-041217-010829
- Benson, M.D., Waddington-Cruz, M., Berk, J.L., Polydefkis, M., Dyck, P.J., Wang, A.K., Plante-Bordeneuve, V., Barroso, F.A., Merlini, G., Obici, L., et al. (2018). Inotersen treatment for patients with hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 22-31. https://doi.org/10.1056/NEJMoa1716793
- CFTR1 (Cystic Fibrosis Mutation Database) (2022). CFMDB Statistics. Retrieved October 22, 2022, from http://www.genet.sickkids.on.ca/ StatisticsPage.html
- CFTR2 (Clinical and Functional TRanslation of CFTR) (2022). CFTR2 Variant List History. Retrieved April 29, 2022, from https://cftr2.org/sites/default/ files/CFTR2_29April2022.xlsx
- Chiba-Falek, O., Kerem, E., Shoshani, T., Aviram, M., Augarten, A., Bentur, L., Tal, A., Tullis, E., Rahat, A., and Kerem, B. (1998). The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C→T mutation. Genomics 53, 276-283. https://doi.org/10.1006/geno.1998.5517
- Clancy, J.P., Rowe, S.M., Bebok, Z., Aitken, M.L., Gibson, R., Zeitlin, P., Berclaz, P., Moss, R., Knowles, M.R., Oster, R.A., et al. (2007). No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am. J. Respir. Cell Mol. Biol. 37, 57-66. https://doi.org/10.1165/rcmb.2006-0173OC
- Clarke, L.A., Awatade, N.T., Felicio, V.M., Silva, I.A., Calucho, M., Pereira, L., Azevedo, P., Cavaco, J., Barreto, C., Bertuzzo, C., et al. (2019). The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for readthrough therapies in cystic fibrosis. Hum. Mutat. 40, 326-334.
- Crooke, S.T. (2007). Antisense Drug Technology: Principles, Strategies, and Applications (2nd Edition) (Boca Raton: CRC Press).
- Crooke, S.T., Baker, B.F., Crooke, R.M., and Liang, X.H. (2021). Antisense technology: an overview and prospectus. Nat. Rev. Drug Discov. 20, 427-453. https://doi.org/10.1038/s41573-021-00162-z
- Crosby, J.R., Zhao, C., Jiang, C., Bai, D., Katz, M., Greenlee, S., Kawabe, H., McCaleb, M., Rotin, D., Guo, S., et al. (2017). Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice. J. Cyst. Fibros. 16, 671-680. https://doi.org/10.1016/j.jcf.2017.05.003
- Cystic Fibrosis Foundation (2021). 2020 Patient Registry Annual Data Report. Retrieved September 15, 2021, from https://www.cff.org/sites/ default/files/2021-10/2019-Patient-Registry-Annual-Data-Report.pdf
- Cystic Fibrosis Foundation (2022). Drug Development Pipeline. Retrieved October 23, 2022, from https://apps.cff.org/trials/pipeline/
- Dang, Y., van Heusden, C., Nickerson, V., Chung, F., Wang, Y., Quinney, N.L., Gentzsch, M., Randell, S.H., Moulton, H.M., Kole, R., et al. (2021). Enhanced delivery of peptide-morpholino oligonucleotides with a small molecule to correct splicing defects in the lung. Nucleic Acids Res. 49, 6100-6113. https://doi.org/10.1093/nar/gkab488
- Darras, B.T., Farrar, M.A., Mercuri, E., Finkel, R.S., Foster, R., Hughes, S.G., Bhan, I., Farwell, W., and Gheuens, S. (2019). An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials. CNS Drugs 33, 919-932. https://doi.org/10.1007/s40263-019-00656-w
- De Boeck, K. and Amaral, M.D. (2016). Progress in therapies for cystic fibrosis. Lancet Respir. Med. 4, 662-674. https://doi.org/10.1016/S2213-2600(16)00023-0
- Dhillon, S. (2020). Viltolarsen: first approval. Drugs 80, 1027-1031. https://doi.org/10.1007/s40265-020-01339-3
- Drevinek, P., Pressler, T., Cipolli, M., De Boeck, K., Schwarz, C., Bouisset, F., Boff, M., Henig, N., Paquette-Lamontagne, N., Montgomery, S., et al. (2020). Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis. J. Cyst. Fibros. 19, 99-107. https://doi.org/10.1016/j.jcf.2019.05.014
- Dukovski, D., Villella, A., Bastos, C., King, R., Finley, D., Kelly, J.W., Morimoto, R.I., Hartl, F.U., Munoz, B., Lee, P.S., et al. (2020). Amplifiers cotranslationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA. J. Cyst. Fibros. 19, 733-741. https://doi.org/10.1016/j.jcf.2020.02.006
- Fiedorczuk, K. and Chen, J. (2022). Mechanism of CFTR correction by type I folding correctors. Cell 185, 158-168.e11. https://doi.org/10.1016/j.cell.2021.12.009
- Finkel, R.S., Mercuri, E., Darras, B.T., Connolly, A.M., Kuntz, N.L., Kirschner, J., Chiriboga, C.A., Saito, K., Servais, L., Tizzano, E., et al. (2017). Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723-1732. https://doi.org/10.1056/NEJMoa1702752
- Friedman, K.J., Kole, J., Cohn, J.A., Knowles, M.R., Silverman, L.M., and Kole, R. (1999). Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J. Biol. Chem. 274, 36193-36199. https://doi.org/10.1074/jbc.274.51.36193
- Giuliano, K.A., Wachi, S., Drew, L., Dukovski, D., Green, O., Bastos, C., Cullen, M.D., Hauck, S., Tait, B.D., Munoz, B., et al. (2018). Use of a highthroughput phenotypic screening strategy to identify amplifiers, a novel pharmacological class of small molecules that exhibit functional synergy with potentiators and correctors. SLAS Discov. 23, 111-121. https://doi.org/10.1177/2472555217729790
- Haggie, P.M., Phuan, P.W., Tan, J.A., Xu, H., Avramescu, R.G., Perdomo, D., Zlock, L., Nielson, D.W., Finkbeiner, W.E., Lukacs, G.L., et al. (2017). Correctors and potentiators rescue function of the truncated W1282Xcystic fibrosis transmembrane regulator (CFTR) translation product. J. Biol. Chem. 292, 771-785. https://doi.org/10.1074/jbc.M116.764720
- Harris, A. (2021). Human Molecular Genetics and the long road to treating cystic fibrosis. Hum. Mol. Genet. 30(R2), R264-R273. https://doi.org/10.1093/hmg/ddab191
- Heijerman, H.G.M., McKone, E.F., Downey, D.G., Van Braeckel, E., Rowe, S.M., Tullis, E., Mall, M.A., Welter, J.J., Ramsey, B.W., McKee, C.M., et al. (2019). Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 394, 1940-1948. https://doi.org/10.1016/S0140-6736(19)32597-8
- Huang, L., Low, A., Damle, S.S., Keenan, M.M., Kuntz, S., Murray, S.F., Monia, B.P., and Guo, S. (2018). Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations. Genome Biol. 19, 4.
- Keating, D., Marigowda, G., Burr, L., Daines, C., Mall, M.A., McKone, E.F., Ramsey, B.W., Rowe, S.M., Sass, L.A., Tullis, E., et al. (2018). VX445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med. 379, 1612-1620. https://doi.org/10.1056/NEJMoa1807120
- Keeling, K.M., Wang, D., Dai, Y., Murugesan, S., Chenna, B., Clark, J., Belakhov, V., Kandasamy, J., Velu, S.E., Baasov, T., et al. (2013). Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression. PLoS One 8, e60478.
- Keenan, M.M., Huang, L., Jordan, N.J., Wong, E., Cheng, Y., Valley, H.C., Mahiou, J., Liang, F., Bihler, H., Mense, M., et al. (2019). Nonsensemediated RNA decay pathway inhibition restores expression and function of W1282X CFTR. Am. J. Respir. Cell Mol. Biol. 61, 290-300. https://doi.org/10.1165/rcmb.2018-0316OC
- Kerem, E. (2004). Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr. Opin. Pulm. Med. 10, 547-552. https://doi.org/10.1097/01.mcp.0000141247.22078.46
- Kerem, E. (2020). ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease. Expert Opin. Investig. Drugs 29, 1347-1354. https://doi.org/10.1080/13543784.2020.1828862
- Khvorova, A. and Watts, J.K. (2017). The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238-248. https://doi.org/10.1038/nbt.3765
- Kim, Y.J., Nomakuchi, T., Papaleonidopoulou, F., Yang, L., Zhang, Q., and Krainer, A.R. (2022a). Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy. Nat. Commun. 13, 2978.
- Kim, Y.J., Sivetz, N., Layne, J., Voss, D.M., Yang, L., Zhang, Q., and Krainer, A.R. (2022b). Exon-skipping antisense oligonucleotides for cystic fibrosis therapy. Proc. Natl. Acad. Sci. U. S. A. 119, e2114858118.
- Kurosaki, T., Popp, M.W., and Maquat, L.E. (2019). Quality and quantity control of gene expression by nonsense-mediated mRNA decay. Nat. Rev. Mol. Cell Biol. 20, 406-420. https://doi.org/10.1038/s41580-019-0126-2
- Labiris, N.R. and Dolovich, M.B. (2003). Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56, 588-599. https://doi.org/10.1046/j.1365-2125.2003.01892.x
- Lentini, L., Melfi, R., Di Leonardo, A., Spinello, A., Barone, G., Pace, A., Palumbo Piccionello, A., and Pibiri, I. (2014). Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay. Mol. Pharm. 11, 653-664. https://doi.org/10.1021/mp400230s
- Linde, L., Boelz, S., Nissim-Rafinia, M., Oren, Y.S., Wilschanski, M., Yaacov, Y., Virgilis, D., Neu-Yilik, G., Kulozik, A.E., Kerem, E., et al. (2007). Nonsensemediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J. Clin. Invest. 117, 683-692. https://doi.org/10.1172/JCI28523
- Michaels, W.E., Bridges, R.J., and Hastings, M.L. (2020). Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells. Nucleic Acids Res. 48, 7454-7467. https://doi.org/10.1093/nar/gkaa490
- Michaels, W.E., Pena-Rasgado, C., Kotaria, R., Bridges, R.J., and Hastings, M.L. (2022). Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis. Proc. Natl. Acad. Sci. U. S. A. 119, e2114886119.
- Middleton, P.G., Mall, M.A., Drevinek, P., Lands, L.C., McKone, E.F., Polineni, D., Ramsey, B.W., Taylor-Cousar, J.L., Tullis, E., Vermeulen, F., et al. (2019). Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N. Engl. J. Med. 381, 1809-1819. https://doi.org/10.1056/NEJMoa1908639
- Moschos, S.A., Usher, L., and Lindsay, M.A. (2017). Clinical potential of oligonucleotide-based therapeutics in the respiratory system. Pharmacol. Ther. 169, 83-103. https://doi.org/10.1016/j.pharmthera.2016.10.009
- Mutyam, V., Libby, E.F., Peng, N., Hadjiliadis, D., Bonk, M., Solomon, G.M., and Rowe, S.M. (2017). Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation. J. Cyst. Fibros. 16, 24-29. https://doi.org/10.1016/j.jcf.2016.09.005
- Nomakuchi, T.T., Rigo, F., Aznarez, I., and Krainer, A.R. (2016). Antisense oligonucleotide-directed inhibition of nonsense-mediated mRNA decay. Nat. Biotechnol. 34, 164-166. https://doi.org/10.1038/nbt.3427
- Oren, Y.S., Avizur-Barchad, O., Ozeri-Galai, E., Elgrabli, R., Schirelman, M.R., Blinder, T., Stampfer, C.D., Ordan, M., Laselva, O., Cohen-Cymberknoh, M., et al. (2022). Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation. J. Cyst. Fibros. 21, 630-636. https://doi.org/10.1016/j.jcf.2021.12.012
- Oren, Y.S., Irony-Tur Sinai, M., Golec, A., Barchad-Avitzur, O., Mutyam, V., Li, Y., Hong, J., Ozeri-Galai, E., Hatton, A., Leibson, C., et al. (2021). Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation. J. Cyst. Fibros. 20, 865-875. https://doi.org/10.1016/j.jcf.2021.06.003
- Ostrowski, L.E., Yin, W., Diggs, P.S., Rogers, T.D., O'Neal, W.K., and Grubb, B.R. (2007). Expression of CFTR from a ciliated cell-specific promoter is ineffective at correcting nasal potential difference in CF mice. Gene Ther. 14, 1492-1501. https://doi.org/10.1038/sj.gt.3302994
- Pascual-Morena, C., Cavero-Redondo, I., Alvarez-Bueno, C., Mesas, A.E., Pozuelo-Carrascosa, D., and Martinez-Vizcaino, V. (2020). Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: a systematic review. Ann. Clin. Transl. Neurol. 7, 1738-1752. https://doi.org/10.1002/acn3.51149
- Pinto, M.C., Silva, I.A., Figueira, M.F., Amaral, M.D., and Lopes-Pacheco, M. (2021). Pharmacological modulation of ion channels for the treatment of cystic fibrosis. J. Exp. Pharmacol. 13, 693-723. https://doi.org/10.2147/JEP.S255377
- Raal, F.J., Santos, R.D., Blom, D.J., Marais, A.D., Charng, M.J., Cromwell, W.C., Lachmann, R.H., Gaudet, D., Tan, J.L., Chasan-Taber, S., et al. (2010). Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375, 998-1006. https://doi.org/10.1016/S0140-6736(10)60284-X
- Ramsey, B.W., Davies, J., McElvaney, N.G., Tullis, E., Bell, S.C., Drevinek, P., Griese, M., McKone, E.F., Wainwright, C.E., Konstan, M.W., et al. (2011). A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663-1672. https://doi.org/10.1056/NEJMoa1105185
- Sanderlin, E.J., Keenan, M.M., Mense, M., Revenko, A.S., Monia, B.P., Guo, S., and Huang, L. (2022). CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway. Nat. Commun. 13, 2344.
- Sasaki, S., Sun, R., Bui, H.H., Crosby, J.R., Monia, B.P., and Guo, S. (2019). Steric inhibition of 5' UTR regulatory elements results in upregulation of human CFTR. Mol. Ther. 27, 1749-1757. https://doi.org/10.1016/j.ymthe.2019.06.016
- Scharner, J., Ma, W.K., Zhang, Q., Lin, K.T., Rigo, F., Bennett, C.F., and Krainer, A.R. (2020). Hybridization-mediated off-target effects of spliceswitching antisense oligonucleotides. Nucleic Acids Res. 48, 802-816. https://doi.org/10.1093/nar/gkz1132
- Sharma, J., Du, M., Wong, E., Mutyam, V., Li, Y., Chen, J., Wangen, J., Thrasher, K., Fu, L., Peng, N., et al. (2021). A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion. Nat. Commun. 12, 4358.
- Shimo, T., Maruyama, R., and Yokota, T. (2018). Designing effective antisense oligonucleotides for exon skipping. Methods Mol. Biol. 1687, 143-155. https://doi.org/10.1007/978-1-4939-7374-3_10
- Shirley, M. (2021). Casimersen: first approval. Drugs 81, 875-879. https://doi.org/10.1007/s40265-021-01512-2
- Shteinberg, M., Haq, I.J., Polineni, D., and Davies, J.C. (2021). Cystic fibrosis. Lancet 397, 2195-2211. https://doi.org/10.1016/S0140-6736(20)32542-3
- Southern, K.W., Murphy, J., Sinha, I.P., and Nevitt, S.J. (2020). Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst. Rev. 12, CD010966.
- Templin, M.V., Levin, A.A., Graham, M.J., Aberg, P.M., Axelsson, B.I., Butler, M., Geary, R.S., and Bennett, C.F. (2000). Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice. Antisense Nucleic Acid Drug Dev. 10, 359-368. https://doi.org/10.1089/oli.1.2000.10.359
- Valley, H.C., Bukis, K.M., Bell, A., Cheng, Y., Wong, E., Jordan, N.J., Allaire, N.E., Sivachenko, A., Liang, F., Bihler, H., et al. (2019). Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells. J. Cyst. Fibros. 18, 476-483. https://doi.org/10.1016/j.jcf.2018.12.001
- Van Goor, F., Hadida, S., Grootenhuis, P.D., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., et al. (2009). Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. U. S. A. 106, 18825-18830. https://doi.org/10.1073/pnas.0904709106
- Voelker, R. (2019). Patients with cystic fibrosis have new triple-drug combination. JAMA 322, 2068.
- Wan, W.B. and Seth, P.P. (2016). The medicinal chemistry of therapeutic oligonucleotides. J. Med. Chem. 59, 9645-9667. https://doi.org/10.1021/acs.jmedchem.6b00551
- Wang, W., Hong, J.S., Rab, A., Sorscher, E.J., and Kirk, K.L. (2016). Robust stimulation of W1282X-CFTR channel activity by a combination of allosteric modulators. PLoS One 11, e0152232.
- Winkler, J. (2013). Oligonucleotide conjugates for therapeutic applications. Ther. Deliv. 4, 791-809. https://doi.org/10.4155/tde.13.47
- Witztum, J.L., Gaudet, D., Freedman, S.D., Alexander, V.J., Digenio, A., Williams, K.R., Yang, Q., Hughes, S.G., Geary, R.S., Arca, M., et al. (2019). Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N. Engl. J. Med. 381, 531-542. https://doi.org/10.1056/NEJMoa1715944
- Zaher, A., ElSaygh, J., Elsori, D., ElSaygh, H., and Sanni, A. (2021). A review of Trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. Cureus 13, e16144.
- Zainal Abidin, N., Haq, I.J., Gardner, A.I., and Brodlie, M. (2017). Ataluren in cystic fibrosis: development, clinical studies and where are we now? Expert Opin. Pharmacother. 18, 1363-1371. https://doi.org/10.1080/14656566.2017.1359255